Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis

FDA Approves Bristol-Myers Squibb's (BMY) New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma

(Updated - February 5, 2021 3:06 PM EST)

Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.

"Today's approval represents... More

Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Truist Securities

Truist Securities raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $66.00 (from $65.00) while maintaining a Hold rating.... More

Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.46, $0.05 better than the analyst estimate of $1.41. Revenue for the quarter came in at $11.07 billion versus the consensus estimate of $10.73 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus... More